ACADIA Pharmaceuticals Inc. (ACAD)

18,63 +0,58 (+3,21%) Börsenschluss: 04:00PM EDT

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia-pharm.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 540

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stephen R. Davis J.D.	CEO & Director	1,03M	N/A	1961
Dr. Srdjan R. Stankovic M.D., M.S.P.H.	Pres	933,1k	2,04M	1957
Mr. Mark C. Schneyer	Exec. VP & CFO	555,49k	N/A	1974
Mr. Brendan P. Teehan	Exec. VP, COO & Head of Commercial	486,47k	N/A	1969
Mr. Austin D. Kim	Exec. VP, Gen. Counsel & Sec.	559,24k	N/A	1964
Mr. James K. Kihara	VP, Chief Accounting Officer & Corp. Controller	N/A	N/A	1981
Mr. Bob Mischler	Sr. VP of Strategy & Technology Operations	N/A	N/A	N/A
Mr. Mark C. Johnson	VP of Investor Relations	N/A	N/A	N/A
Ms. Julie Fisher	Sr. VP of Marketing & Commercial Strategy	N/A	N/A	N/A
Ms. Holly Valdiviez	Sr. VP & Head of Sales	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.s ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 6. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 8, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.